Fly News Breaks for February 25, 2020
Feb 25, 2020 | 11:40 EDT
Citi analyst Mohit Bansal said that Alexion management reported during a broker conference this morning that the company will not be moving forward with ABY-039 after a review of the drug's preliminary Phase 1 data given risks of immunogenicity associated with bacterial sequences. He believes this removes a "key" 2020 catalyst that some investors were looking toward, adding that ABY-039 was "closely watched because it would have been a truly [subcutaneous] due to its smaller size." The analyst, who keeps a Buy rating on Alexion shares, continues to think the stock needs near-term catalysts to drive multiple expansion and shift the narrative away from Soliris competition. Bansal also noted that Alexion has another anti-FcRn candidate, ALXN1830, though "investors are less excited by this asset."
News For ALXN From the Last 2 Days
Oct 20, 2020 | 13:45 EDT
Bullish option flow detected in Alexion with 3,811 calls trading, 1.2x expected, and implied vol increasing almost 3 points to 52.01%. 11/6 weekly 110 puts and 10/23 weekly 130 calls are the most active options, with total volume in those strikes near 3,300 contracts. The Put/Call Ratio is 0.53. Earnings are expected on October 28th.